CYBeR-CARE Inc, the telehealth technology innovator, recently received clearance from the FDA to market its Blood Glucose Monitoring System (Glucometer). The Glucometer will be integrated with the Electronic HouseCall System family of products and will provide the industry with an economically priced tool with several technological advantages over current industry offerings.

Packet technology benefits system users by simultaneously transmitting data received from the Glucometer along with voice and visual information. All information is received in real-time by the caregiver and is available to payors and caregivers through the secure CYBeR-CARE network. Caregivers can measure results against historical data, from the Glucometer and other monitoring tools available on the Electronic HouseCall System to enable them to deliver better care and more effective disease management treatment.

"We are pleased to be able to announce the FDA approval for our electronic Blood Glucose Monitoring System," said Mike Lemnitzer, vice president of Business Development, CyberCare Technologies. "This tool significantly expands our target market by allowing at home remote monitoring of the diabetic patient."

According to the American Diabetes Association, there are 15.7 million diabetics in the U.S., of which 5.4 million are undiagnosed.

The product underwent clinical trials at the nationally renowned Shepherd Center, a specialty hospital located in Atlanta, and will be available for shipment in January.